Article Listing - Novartis’ Afinitor meets primary endpoint in Ph III SEGAs brain tumor study
PFIZER INVESTS IN NEUROGEN RESEARCH
17 February 1992
US health care concern, Pfizer, has committed itself to providing around $50 million over the next five years for research...
FDA CRITERIA FOR PHARMACIES
17 February 1992
The US Food and Drug Administra-tion is close to issuing new criteria aimed at curbing the unauthorized manufacture of approved...
BIO-MERIEUX NEEDS NEW FINANCE
17 February 1992
The major French producer of in vitro diagnostic products, Bio-Merieux, plans to become one of the ten world diagnostic market...
OUTLOOK FOR FRENCH PHARMA STOCKS
17 February 1992
Although pricing of pharmaceutical products in France has lately been more favorable, it remains undeniably difficult, according to Baring Securities'...
US MARKET FOR FLU TREATMENTS
17 February 1992
The proliferation of flu remedies currently appearing on US drugstore shelves is more a product of marketing than medical breakthroughs,...
US GENERIC DRUG MARKET TO 1995
17 February 1992
The US market for generic drugs will more than double from a value of $5.5 billion in 1991 to reach...
PHILIPPINES DOUBT OVER CEPT SCHEME
17 February 1992
The pharmaceutical industry in the Philippines may not yet be strong enough to compete with the industries of the other...
DRUG APPROVAL CHANGE IN MALAYSIA
17 February 1992
At the end of 1991, the Drug Control Authority of the Malay- sian Ministry of Health implemented new procedures...
US FDA BANS COPIED ZALCITABINE
17 February 1992
The US Food and Drug Administra-tion has banned the sale of an unauthorized copy of Hoffmann-La Roche's AIDS therapy Hivid...
BIOCRAFT SETS SIGHTS ON GENERIC CECLOR
17 February 1992
At least one competitor has set its sights on capturing some of the market which will be left exposed when...
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
